These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 22634049)

  • 1. Statins increase cytochrome P450 4F3-mediated eicosanoids production in human liver cells: a PXR dependent mechanism.
    Plée-Gautier E; Antoun J; Goulitquer S; Le Jossic-Corcos C; Simon B; Amet Y; Salaün JP; Corcos L
    Biochem Pharmacol; 2012 Aug; 84(4):571-9. PubMed ID: 22634049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP4F3B is induced by PGA1 in human liver cells: a regulation of the 20-HETE synthesis.
    Antoun J; Goulitquer S; Amet Y; Dreano Y; Salaun JP; Corcos L; Plée-Gautier E
    J Lipid Res; 2008 Oct; 49(10):2135-41. PubMed ID: 18566475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line.
    Bertrand-Thiebault C; Masson C; Siest G; Batt AM; Visvikis-Siest S
    J Cardiovasc Pharmacol; 2007 May; 49(5):306-15. PubMed ID: 17513950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of phenobarbital-inducible cytochrome P450 2B1/2 mRNA by lovastatin and oxysterols in primary cultures of adult rat hepatocytes.
    Kocarek TA; Schuetz EG; Guzelian PS
    Toxicol Appl Pharmacol; 1993 Jun; 120(2):298-307. PubMed ID: 8511800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP4F3B expression is associated with differentiation of HepaRG human hepatocytes and unaffected by fatty acid overload.
    Madec S; Cerec V; Plée-Gautier E; Antoun J; Glaise D; Salaun JP; Guguen-Guillouzo C; Corlu A
    Drug Metab Dispos; 2011 Oct; 39(10):1987-96. PubMed ID: 21778351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha.
    Ng VY; Huang Y; Reddy LM; Falck JR; Lin ET; Kroetz DL
    Drug Metab Dispos; 2007 Jul; 35(7):1126-34. PubMed ID: 17431031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPARγ-dependent pathway.
    Walther U; Emmrich K; Ramer R; Mittag N; Hinz B
    Oncotarget; 2016 Mar; 7(9):10345-62. PubMed ID: 26863638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression.
    Li T; Chiang JY
    Drug Metab Dispos; 2006 May; 34(5):756-64. PubMed ID: 16455805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes.
    Howe K; Sanat F; Thumser AE; Coleman T; Plant N
    Xenobiotica; 2011 Jul; 41(7):519-29. PubMed ID: 21476904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system.
    Raucy J; Warfe L; Yueh MF; Allen SW
    J Pharmacol Exp Ther; 2002 Oct; 303(1):412-23. PubMed ID: 12235278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mevalonate deprivation mediates the impact of lovastatin on the differentiation of murine 3T3-F442A preadipocytes.
    Elfakhani M; Torabi S; Hussein D; Mills N; Verbeck GF; Mo H
    Exp Biol Med (Maywood); 2014 Mar; 239(3):293-301. PubMed ID: 24477821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways.
    Cerveny L; Svecova L; Anzenbacherova E; Vrzal R; Staud F; Dvorak Z; Ulrichova J; Anzenbacher P; Pavek P
    Drug Metab Dispos; 2007 Jul; 35(7):1032-41. PubMed ID: 17392393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activating and Inhibitory Functions of WNT/β-Catenin in the Induction of Cytochromes P450 by Nuclear Receptors in HepaRG Cells.
    Thomas M; Bayha C; Vetter S; Hofmann U; Schwarz M; Zanger UM; Braeuning A
    Mol Pharmacol; 2015 Jun; 87(6):1013-20. PubMed ID: 25824487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor.
    Yang J; Yan B
    Toxicol Sci; 2007 Jan; 95(1):13-22. PubMed ID: 17003103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sterol regulatory element binding protein 1 interacts with pregnane X receptor and constitutive androstane receptor and represses their target genes.
    Roth A; Looser R; Kaufmann M; Meyer UA
    Pharmacogenet Genomics; 2008 Apr; 18(4):325-37. PubMed ID: 18334917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
    McAnally JA; Gupta J; Sodhani S; Bravo L; Mo H
    Exp Biol Med (Maywood); 2007 Apr; 232(4):523-31. PubMed ID: 17392488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induced CYP3A4 expression in confluent Huh7 hepatoma cells as a result of decreased cell proliferation and subsequent pregnane X receptor activation.
    Sivertsson L; Edebert I; Palmertz MP; Ingelman-Sundberg M; Neve EP
    Mol Pharmacol; 2013 Mar; 83(3):659-70. PubMed ID: 23264496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lovastatin Differentially Affects Neuronal Cholesterol and Amyloid-β Production in vivo and in vitro.
    Mendoza-Oliva A; Ferrera P; Fragoso-Medina J; Arias C
    CNS Neurosci Ther; 2015 Aug; 21(8):631-41. PubMed ID: 26096465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion.
    Masuyama H; Suwaki N; Tateishi Y; Nakatsukasa H; Segawa T; Hiramatsu Y
    Mol Endocrinol; 2005 May; 19(5):1170-80. PubMed ID: 15650019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.